据钢铁奥比斯(Steel Orbis)的一份报告称,德国钢铁制造商蒂森克虏伯(Thyssenkrupp)的西班牙子公司蒂森克虏伯Galmed计划关闭其年产45万吨的萨贡托(Sagunto)工厂,其工厂所有员工将面临...查看全文
Galmed(GLMD)2023-11-23 05:25
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-23-042486 Act: 34 Size: 280 KB 网页链接查看全文
Galmed(GLMD)2023-11-21 05:45
$Galmed(GLMD)$ 6-K Report of foreign issuer [Rules 13a-16 and 15d-16] Accession Number: 0001493152-23-042127 Act: 34 Size: 33 KB 网页链接查看全文
Galmed(GLMD)2023-11-23 05:55
$Galmed(GLMD)$ POS AM Post-Effective amendments for registration statement Accession Number: 0001493152-23-042520 Act: 33 Size: 612 KB 网页链接查看全文
未来与乐2023-12-05 14:11
跨国公司,基础数据,670家子公司,19.9万人,平均每家公司300人,年收入380亿。中国很多皮包子公司。
据钢铁奥比斯(Steel Orbis)的一份报告称,德国钢铁制造商蒂森克虏伯(Thyssenkrupp)的西班牙子公司蒂森克虏伯Galmed计划关闭其年产45万吨的萨贡托(Sagunto)工厂,其工厂所有员工将面临...查看全文
F1watch2023-07-14 05:20
F-1/A - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-07-13 AccNo: 0001493152-23-024507 Size: 822 KB 网页链接查看全文
F1watch2023-07-13 05:40
F-1/A - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-07-12 AccNo: 0001493152-23-024354 Size: 1 MB 网页链接查看全文
F1watch2023-06-28 20:40
F-1/A - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-06-28 AccNo: 0001493152-23-022693 Size: 1 MB 网页链接查看全文
F1watch2023-06-17 04:20
F-1 - Galmed Pharmaceuticals Ltd. (0001595353) (Filer) Filed: 2023-06-16 AccNo: 0001493152-23-021672 Size: 1 MB 网页链接查看全文
蹊之美股生物医药2021-11-02 22:10
作者:王医生
微信公众号:蹊之美股生物医药 / CaesarBiotech
标的公司:Galmed Pharmaceuticals Ltd.(NASDAQ:GLMD)
Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD)是一家临床阶段的肝脏、代谢和炎症疾病生物制药公司,今天宣布了ARMOR 3期研究开放标签部分的前16名患者接受预定的...查看全文
蹊之美股生物医药2021-08-03 23:10
Gainers:
Infinity Pharmaceuticals (NASDAQ:INFI)+38%
Exicure (NASDAQ:XCUR) +34%
Ra Medical Systems (NYSE:RMED) +18%
Galmed Pharmaceuticals (NASDAQ:GLMD) +17%
Lava Therapeutics (NASDAQ:LVTX) +5%
Losers:
Immunovant (NASDAQ:IMVT) -26%...查看全文
美通社2021-04-03 23:45
中国苏州和美国马里兰州罗克维尔市2021年4月2日 /美通社/ -- 致力于在肿瘤、乙肝及与衰老相关疾病等治疗领域开发创新药物的处于临床阶段的研发企业——亚盛医药(6855.HK)日前宣布,公司任命知名肿瘤学专家David Sidransky博士为独立非执行董事,该任命自2021年3月31日起生效。
Sidransky博士...查看全文
洛其飞2021-02-15 11:50
$Galmed(GLMD)$ 目前全球领先的NASH新药研发公司,如果今年能第一家取得FDA该类新药的审批,妥妥超过nvax去年的涨幅,持续关注nash类新药研发进展。查看全文
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2018-01-26 AccNo: 0001144204-18-004033 Size: 70 KB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-03 AccNo: 0001144204-18-000341 Size: 8 MB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2018-01-02 AccNo: 0001144204-18-000046 Size: 96 KB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 424B5 - Prospectus [Rule 424(b)(5)] Filed: 2017-12-22 AccNo: 0001144204-17-065093 Size: 1 MB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-12-22 AccNo: 0001144204-17-065092 Size: 335 KB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2017-12-18 AccNo: 0001013594-17-000827 Size: 80 KB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-11-09 AccNo: 0001144204-17-057429 Size: 304 KB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 美东时间 2017-11-09 盘前 披露财报,预期EPS -0.27 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] Filed: 2017-10-05 AccNo: 0001144204-17-051431 Size: 61 KB 网页链接
$Galmed Pharmaceuticals Ltd. - Ordinary Shares(GLMD)$ D - Notice of Exempt Offering of Securities Filed: 2017-08-15 AccNo: 0001144204-17-043518 Size: 12 KB 网页链接